These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

209 related articles for article (PubMed ID: 33504193)

  • 41. Efficacy and safety of combined radiotherapy with EGFR inhibitors and chemotherapy for laryngeal organ preservation in patients with locally advanced hypopharyngeal carcinomas.
    Zhang X; Wang J; Wu W; Liu M; Zhao F; Du L; Huang D; Yang S; Ma L
    Curr Cancer Drug Targets; 2014; 14(6):589-98. PubMed ID: 25039274
    [TBL] [Abstract][Full Text] [Related]  

  • 42. [Induction chemotherapy with docetaxel plus cisplatin (TP regimen) followed by concurrent chemoradiotherapy with TP regimen versus cisplatin in treating locally advanced nasopharyngeal carcinoma].
    Xie FY; Zou GR; Hu WH; Qi SN; Peng M; Li JS
    Ai Zheng; 2009 Mar; 28(3):279-85. PubMed ID: 19619443
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Cetuximab or nimotuzumab plus intensity-modulated radiotherapy versus cisplatin plus intensity-modulated radiotherapy for stage II-IVb nasopharyngeal carcinoma.
    You R; Sun R; Hua YJ; Li CF; Li JB; Zou X; Yang Q; Liu YP; Zhang YN; Yu T; Cao JY; Zhang MX; Jiang R; Mo HY; Guo L; Cao KJ; Lin AH; Qian CN; Sun Y; Ma J; Chen MY
    Int J Cancer; 2017 Sep; 141(6):1265-1276. PubMed ID: 28577306
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Prospective, Multicenter, Phase 2 Trial of Induction Chemotherapy Followed by Bio-Chemoradiotherapy for Locally Advanced Recurrent Nasopharyngeal Carcinoma.
    Ng WT; Ngan RKC; Kwong DLW; Tung SY; Yuen KT; Kam MKM; Sze HCK; Yiu HHY; Chan LLK; Lung ML; Lee AWM
    Int J Radiat Oncol Biol Phys; 2018 Mar; 100(3):630-638. PubMed ID: 29413277
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Concurrent chemoradiotherapy with nedaplatin versus cisplatin in stage II-IVB nasopharyngeal carcinoma: A cost-effectiveness analysis.
    Liao W; Huang J; Wu Q; Zhu G; Wang X; Wen F; Zhang P; Zhang N; Li Q
    Oral Oncol; 2019 Jun; 93():15-20. PubMed ID: 31109691
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Efficacy of nimotuzumab in combination with immunotherapy for a young recurrent cervical cancer patient: a case report and literature review.
    Shi M; Zhang Y
    Anticancer Drugs; 2024 Aug; 35(7):644-652. PubMed ID: 38950136
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Targeting EGFR in nasopharyngeal carcinoma.
    Kyrodimos E; Chrysovergis A; Mastronikolis N; Tsiambas E; Ragos V; Roukas D; Fotiades P; Papanikolaou V
    J BUON; 2021; 26(3):759-761. PubMed ID: 34268932
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Comparison of induction chemotherapy plus concurrent chemoradiotherapy and induction chemotherapy plus radiotherapy in locally advanced nasopharyngeal carcinoma.
    Wang Q; Xu G; Xia Y; Zuo J; Zeng G; Xue Z; Cao R; Xiong W; Li W
    Oral Oncol; 2020 Dec; 111():104925. PubMed ID: 32721816
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Effect of induction chemotherapy with cisplatin, fluorouracil, with or without taxane on locoregionally advanced nasopharyngeal carcinoma: a retrospective, propensity score-matched analysis.
    Liu GY; Lv X; Wu YS; Mao MJ; Ye YF; Yu YH; Liang H; Yang J; Ke LR; Qiu WZ; Huang XJ; Li WZ; Guo X; Xiang YQ; Xia WX
    Cancer Commun (Lond); 2018 May; 38(1):21. PubMed ID: 29764487
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Non-endemic locoregionally advanced nasopharyngeal carcinoma: long-term outcome after induction plus concurrent chemoradiotherapy in everyday clinical practice.
    Boscolo-Rizzo P; Tirelli G; Mantovani M; Baggio V; Lupato V; Spinato G; Gava A; Da Mosto MC
    Eur Arch Otorhinolaryngol; 2015 Nov; 272(11):3491-8. PubMed ID: 25367705
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Inhibition of autophagy by chloroquine makes chemotherapy in nasopharyngeal carcinoma more efficient.
    Aga T; Endo K; Tsuji A; Aga M; Moriyama-Kita M; Ueno T; Nakanishi Y; Hatano M; Kondo S; Sugimoto H; Wakisaka N; Yoshizaki T
    Auris Nasus Larynx; 2019 Jun; 46(3):443-450. PubMed ID: 30514592
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Combining Nimotuzumab With Chemotherapy for Patients With Locally Advanced and Intermediate-Stage Nasopharyngeal Cancer: A Retrospective Comparison Study Using Five-Year, Real-World Survival Data.
    Rachman A; Sari SR; Munandar A; Adham M; Hutajulu SH
    Cureus; 2023 Nov; 15(11):e48804. PubMed ID: 38098929
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Raltitrexed versus 5-fluorouracil with cisplatin and concurrent radiotherapy for locally advanced nasopharyngeal carcinoma: An open labeled, randomized, controlled, and multicenter clinical trial.
    Yan P; Yin H; Guo W; Sun X; Li F; Huang S; Bian X; Wang F; Zhang F; Wang B; Zhou H; Zhou C; Yin L; Jiang X; Jiang N; Wu J; Liu J; Song D; He X
    Cancer Med; 2020 Sep; 9(17):6166-6172. PubMed ID: 32657029
    [TBL] [Abstract][Full Text] [Related]  

  • 54. A phase II multicenter randomized controlled trial to compare standard chemoradiation with or without recombinant human endostatin injection (Endostar) therapy for the treatment of locally advanced nasopharyngeal carcinoma: Long-term outcomes update.
    Li Y; Tian Y; Jin F; Wu W; Long J; Ouyang J; Zhou Y
    Curr Probl Cancer; 2020 Feb; 44(1):100492. PubMed ID: 32035692
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy.
    Finazzi T; Rordorf T; Ikenberg K; Huber GF; Guckenberger M; Garcia Schueler HI
    BMC Cancer; 2018 Apr; 18(1):395. PubMed ID: 29625593
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Research on the efficacy of cisplatin and nimotuzumab combined with concurrent chemoradiotherapy on locally advanced cervical cancer.
    Cao Y; Deng L; Lian S; Jiang Y
    J BUON; 2019; 24(5):2013-2019. PubMed ID: 31786869
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Nimotuzumab combined with concurrent chemoradiotherapy in Japanese patients with esophageal cancer: A phase I study.
    Kato K; Ura T; Koizumi W; Iwasa S; Katada C; Azuma M; Ishikura S; Nakao Y; Onuma H; Muro K
    Cancer Sci; 2018 Mar; 109(3):785-793. PubMed ID: 29285832
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Prognostic and predictive significance of nuclear HIF1α expression in locally advanced HNSCC patients treated with chemoradiation with or without nimotuzumab.
    Patel U; Pandey M; Kannan S; Samant TA; Gera P; Mittal N; Rane S; Patil A; Noronha V; Joshi A; Patil VM; Prabhash K; Mahimkar MB
    Br J Cancer; 2020 Dec; 123(12):1757-1766. PubMed ID: 32939054
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Cetuximab versus nimotuzumab for the treatment of advanced nasopharyngeal carcinoma: A network meta-analysis.
    Yuan C; Xu XH; Xu L; Liu Y; Sun M; Ni LH; Wang XL; Chen Z; Zhang K; Wan HL; Zeng G
    J BUON; 2017; 22(4):1004-1010. PubMed ID: 28952220
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Use of nimotuzumab combined with cisplatin in treatment of nasopharyngeal carcinoma and its effect on expressions of VEGF and MMP-2.
    Qu L; Wang JH; Du JX; Kang P; Niu XQ; Yin LZ
    Clin Transl Oncol; 2021 Jul; 23(7):1342-1349. PubMed ID: 33517541
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.